Patents by Inventor Andrew M. Scharenberg

Andrew M. Scharenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294946
    Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.
    Type: Application
    Filed: April 10, 2024
    Publication date: September 5, 2024
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Karen Sommer, Samuel West, Yuchi Chiang Honaker, Ryo Takeuchi
  • Publication number: 20240287452
    Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
    Type: Application
    Filed: February 14, 2024
    Publication date: August 29, 2024
    Inventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
  • Patent number: 11987804
    Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: May 21, 2024
    Assignee: Seattle Children's Hospital
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Karen Sommer, Samuel West, Yuchi Chiang Honaker, Ryo Takeuchi
  • Patent number: 11959073
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: April 16, 2024
    Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
  • Publication number: 20240117352
    Abstract: Aspects of the invention described herein concern the incorporation of a FOXP3 cDNA (e.g., full-length human codon-optimized cDNA) into a FOXP3 gene or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human CD34+ cells or cells derived from edited CD34+ cells. In some embodiments, guide RNA sequences that are directed to FOXP3, AAVS1, or other candidate loci are used for CRISPR/Cas9-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided.
    Type: Application
    Filed: June 16, 2023
    Publication date: April 11, 2024
    Inventors: David J. Rawlings, Iram F. Khan, Yuchi Chiang Honaker, Swati Singh, Karen Sommer, Andrew M. Scharenberg
  • Publication number: 20240117008
    Abstract: The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.
    Type: Application
    Filed: August 8, 2023
    Publication date: April 11, 2024
    Inventor: Andrew M. Scharenberg
  • Publication number: 20240102001
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Application
    Filed: December 1, 2023
    Publication date: March 28, 2024
    Applicant: SEATTLE CHILDREN'S HOSPITAL (dba SEATTLE CHILDREN'S RESEARCH INSTITUTE)
    Inventors: Andrew M. SCHARENBERG, Michael T. CERTO, Kamila Sabina GWIAZDA
  • Patent number: 11939594
    Abstract: The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 26, 2024
    Assignee: Seattle Children's Hospital
    Inventors: David J. Rawlings, Richard James, Shaun W. Jackson, Iram Khan, King Hung, Andrew M. Scharenberg
  • Publication number: 20240033300
    Abstract: Disclosed are methods of making a genetically cell that expressed FOXP3 and methods of treatment. In some embodiments, the method comprises providing a first nucleotide sequence, wherein the first nucleotide sequence comprises a coding strand, the coding strand comprising one or more regulatory elements and a FOXP3 gene or portion thereof providing a nuclease and performing a gene editing process on the first nucleotide sequence, which edits said one or more regulatory elements, and optionally edits the FOXP3 gene or portion thereof. Methods of treating a subject suffering from an autoimmune disease and subjects suffering the effects of organ transplantation are also provided.
    Type: Application
    Filed: June 16, 2023
    Publication date: February 1, 2024
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Troy Torgerson
  • Patent number: 11873479
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: January 16, 2024
    Assignee: SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Andrew M. Scharenberg, Michael T. Certo, Kamila Sabina Gwiazda
  • Patent number: 11753460
    Abstract: The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Seattle Children's Hospital
    Inventor: Andrew M. Scharenberg
  • Patent number: 11713459
    Abstract: Aspects of the invention described herein concern the incorporation of a FOXP3 cDNA (e.g., full-length human codon-optimized cDNA) into a FOXP3 gene or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human CD34+ cells or cells derived from edited CD34+ cells. In some embodiments, guide RNA sequences that are directed to FOXP3, AAVS1, or other candidate loci are used for CRISPR/Cas9-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: August 1, 2023
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: David J. Rawlings, Iram F. Khan, Yuchi Chiang Honaker, Swati Singh, Karen Sommer, Andrew M. Scharenberg
  • Patent number: 11712454
    Abstract: Disclosed are methods of making a genetically cell that expressed FOXP3 and methods of treatment. In some embodiments, the method can providing a first nucleotide sequence, wherein the first nucleotide sequence comprises a coding strand, the coding strand comprising one or more regulatory elements and a FOXP3 gene or portion thereof providing a nuclease and performing a gene editing process on the first nucleotide sequence, which edits said one or more regulatory elements, and optionally edits the FOXP3 gene or portion thereof. Methods of treating a subject suffering from an autoimmune disease and subjects suffering the effects of organ transplantation are also provided.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: August 1, 2023
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Troy Torgerson
  • Publication number: 20230054471
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 23, 2023
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • Patent number: 11400169
    Abstract: Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 2, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Andrew M. Scharenberg, Kyle Jacoby, Alexandra E. Grier
  • Publication number: 20210340573
    Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.
    Type: Application
    Filed: April 25, 2019
    Publication date: November 4, 2021
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Karen Sommer, Samuel West, Yuchi Chiang Honaker, Ryo Takeuchi
  • Publication number: 20210309995
    Abstract: Some embodiments of the methods and compositions provided herein relate to modifying hemoglobin loci, such as hemoglobin-related mutations including sickle cell mutations. Some embodiments relate to modification of a sickle cell mutation through introduction of a phosphodiester DNA strand break at the site of the sickle cell mutation.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 7, 2021
    Inventors: David J. Rawlings, Sowmya Pattabhi, Andrew M. Scharenberg, Kyle Jacoby
  • Publication number: 20210261946
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 26, 2021
    Applicant: SEATTLE CHILDREN'S HOSPITAL (dba SEATTLE CHILDREN'S RESEARCH INSTITUTE)
    Inventors: Andrew M. SCHARENBERG, Michael T. CERTO, Kamila Sabina GWIAZDA
  • Publication number: 20210253652
    Abstract: Aspects of the invention described herein concern targeting of a FOXP3 cDNA, e.g., full-length human-codon optimized, into a FOXP3 locus or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human lymphocyte. The compositions and materials described herein provide specificity for CRISPR/Cas-mediated gene regulation of murine, non-human primates or human FOXP3. Guide RNA sequences are used to target the FOXP3, AAVS1, and other candidate loci for CRISPR/Cas-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided. The alternative compositions described herein can be delivered in the form of Ribonucleoprotein (RNP) and may be used to target human and/or non-human primate FOXP3. Reagents are comprised of novel guide RNA sequences and can generate high frequency of on-target cleavage in combination with a Cas protein and novel gene delivery cassettes including FOXP3 cDNA+/?other cis linked gene products.
    Type: Application
    Filed: April 25, 2019
    Publication date: August 19, 2021
    Inventors: Andrew M. Scharenberg, David J. Rawlings, Karen Sommer, Yuchi Chiang Honaker, Iram F. Khan, Troy Torgerson
  • Publication number: 20210254043
    Abstract: The present disclosure relates to the co-expression of an endonuclease with an end-processing enzyme for the purpose of enhanced processing of the polynucleotide ends generated by endonuclease cleavage.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 19, 2021
    Applicant: SEATTLE CHILDREN'S HOSPITAL (dba SEATTLE CHILDREN'S RESEARCH INSTITUTE)
    Inventors: Andrew M. SCHARENBERG, Michael T. CERTO, Kamila Sabina GWIAZDA